TABLE 2.
Characteristic of the total cohort and the study population matched on propensity score for patients with therapeutic anticoagulation use and unexposed patients
| Total cohort | Propensity score‐matched cohort | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic AC use (n = 190) | No therapeutic AC use (n = 964) | Therapeutic AC use (n = 164) | No therapeutic AC use (n = 410) | |||||||||
| Characteristic | n | (%) | n | (%) | P‐value | St. Diff. 1 | n | (%) | n | (%) | P‐value | St. Diff. 1 |
| Age, median (IQR), y | 76 | (72–82) | 68 | (57–76) | <.001 | 0.89a | 76 | (71‐82) | 76 | (70–82) | .70 | 0.035 |
| Females | 55 | (29) | 364 | (38) | .02 | 0.19 | 53 | (32) | 132 | (32) | .98 | 0.0026 |
| BMI, median (IQR), kg/m2 | 27.6 | (24.0–31.1) | 27.6 | (25.0–30.8) | .73 | 0.03 | 27.6 | (24.4–31.7) | 27.7 | (24.8–30.8) | .91 | 0.010 |
| Cardiovascular disease | ||||||||||||
| Hypertension | 112 | (59) | 341 | (35) | <.001 | 0.49a | 96 | (58) | 213 | (52) | .15 | 0.13 |
| Obstructive CAD | 52 | (27) | 96 | (10) | <.001 | 0.46a | 42 | (26) | 83 | (20) | .16 | 0.13 |
| Myocardial infarction | 30 | (16) | 80 | (8) | <.001 | 0.23 | 22 | (13) | 59 | (14) | .76 | 0.028 |
| Heart failure | 40 | (21) | 17 | (2) | <.001 | 0.64a | 17 | (10) | 17 | (4) | .004 | 0.24 |
| Nonischaemic cardiomyopathy | 12 | (6) | 15 | (2) | <.001 | 0.25a | 8 | (5) | 14 | (3) | .41 | 0.073 |
| Previous heart surgery | 18 | (9) | 25 | (3) | <.001 | 0.29a | 13 | (8) | 24 | (6) | .36 | 0.082 |
| Electronic heart device | 13 | (7) | 12 | (12) | <.001 | 0.29a | 7 | (4) | 11 | (3) | .33 | 0.086 |
| CVA | 37 | (19) | 99 | (10) | <.001 | 0.26a | 34 | (21) | 73 | (18) | .42 | 0.074 |
| Peripheral artery disease | 20 | (11) | 41 | (4) | <.001 | 0.24 | 18 | (11) | 33 | (8) | .27 | 0.10 |
| Diabetes mellitus | 52 | (27) | 210 | (22) | .09 | 0.13 | 47 | (29) | 110 | (27) | .66 | 0.041 |
| Chronic pulmonary disease | 53 | (28) | 225 | (23) | .18 | 0.10 | 43 | (26) | 107 | (26) | .98 | 0.0028 |
| Active malignancy | 43 | (23) | 169 | (18) | .10 | 0.13 | 38 | (23) | 91 | (22) | .80 | 0.023 |
| Immunosuppressant use | 23 | (12) | 102 | (11) | .54 | 0.05 | 19 | (12) | 55 | (13) | .56 | 0.055 |
| No ICU policy | 114 | (60) | 268 | (28) | <.001 | 0.69a | 92 | (56) | 218 | (53) | .53 | 0.059 |
AC, anticoagulation; BMI, body mass index; CAD, coronary artery disease; CVA, cerebrovascular accident; ICU, intensive care unit; IQR, interquartile range.
1
Standardized differences to compare the distribution of covariates between the exposure groups.
a
St. Diff >0.25, the covariate is not balanced between the 2 groups.